CD274 and hereditary clear cell renal cell carcinoma: Therapeutic targeting of the PD-1/PD-L1 immune regulatory axis has led to meaningful results in the treatment of many solid tumors, including melanoma, renal cell carcinoma, NSCLC, and head & neck squamous cell carcinoma [7].